Gilead says drug profits must stay high to pay for `innovation,` but 100% of its profits went to shareholders
(LA Times Kings)

With high drug prices still in the political crosshairs on Capitol Hill, pharmaceutical industry bosses are at pains to explain why a cure for hepatitis-C has to cost a budget-busting $1,000 per pill, or a promising cancer treatment should carry a list price of $373,000. That duty most recently...